Opalia is a Montreal-based company producing animal-free dairy proteins using bovine mammary cell culture. We grow the cells that make milk proteins, without growing a cow. This post explains what we are building, why we started in Montreal, and what the cell culture approach means for the dairy supply chain.
Why animal-free dairy proteins, and why now
The problem with conventional dairy is not primarily taste or nutrition, it is the supply chain. Producing casein and whey proteins at scale requires maintaining large bovine herds, with all the land, water, and emissions that entails. The IDF's 2022 life cycle analysis puts water consumption for conventional casein at roughly 4,600 liters per kilogram of protein, and land use for grazing and feed crops at around 170 square meters per kilogram. These are not marginal inputs.
At the same time, plant-based dairy alternatives have captured a meaningful share of the dairy market but have consistently fallen short of dairy's functional performance in applications that depend on the specific structural behavior of casein micelles or native whey proteins. The gap is real and it is structural: pea protein and oat protein do not form the same heat-induced gels, emulsions, or rennet-coagulated structures as dairy proteins because they are fundamentally different molecules doing fundamentally different things in nature.
The question we started with was whether there is a path to producing the same proteins, with the same functional behavior, without the herd. Not an alternative, not a substitute, but the actual protein that dairy has always produced.
How mammary cell culture works
Bovine mammary epithelial cells are the cells in a cow's udder that make milk. In the mammary gland, they are stimulated by hormones including prolactin and hydrocortisone to express and secrete a characteristic set of proteins: predominantly casein variants (beta-Casein, alpha-S1-Casein, kappa-Casein) and whey proteins (beta-Lactoglobulin, alpha-Lactalbumin). These proteins are assembled into casein micelles in and around the cell and secreted into the milk.
In cell culture, we maintain a bovine mammary epithelial cell line in bioreactors, provide the cells with nutrients and hormones that mimic lactogenic conditions, and collect the conditioned media where the cells have secreted their milk proteins. The cells do not know they are in a bioreactor. They respond to the hormonal signals the same way they would in the mammary gland and produce the same proteins through the same biological machinery.
The downstream process takes that conditioned media through clarification, filtration, and chromatographic purification to isolate specific protein fractions at food-grade purity. Our current primary product is BC-1, a beta-Casein fraction with greater than 94% purity by HPLC from 12 consecutive pilot production batches in our 200 L bioreactor.
What we built in the first year
Jennifer and Marcus spent years working with mammalian cell culture in pharmaceutical and food research settings before starting Opalia in Montreal in 2024. The founding question was not whether bovine mammary cells could be cultured, that was established literature. The question was whether the production process could be controlled well enough to achieve consistent food-grade protein quality, and whether an AI optimization layer could make each batch learn from the previous one.
In our first year, we built out a pilot bioreactor facility at our Montreal location, established a cell line, developed the downstream purification protocol for BC-1, ran 12 pilot production batches, and built the optimization feedback loop that has improved yield 31% from batch 1 to batch 12. Dr. Priya Nair joined as Head of Protein Science to lead the characterization and specification work that the food manufacturer evaluation process requires.
We supply protein on a pilot-quantity basis to formulation partners through our early-access program. Every sample comes with full HPLC purity data, mass spectrometry molecular weight confirmation, batch consistency statistics, and handling documentation. The formulation partnerships we are building are working relationships where our protein science team engages directly with the manufacturer's formulation team, not a catalog sale.
Why Montreal
Montreal was not a default choice. We chose it because the infrastructure was right. McGill and Universite de Montreal have strong protein biochemistry and bioprocess engineering research programs. The pharmaceutical biologics manufacturing corridor in Montreal and Laval gives us access to mammalian cell culture equipment suppliers, contract testing labs, and people with hands-on bioreactor experience in the local labor market. The provincial and federal applied research support programs through NRC-IRAP have been accessible and useful for a small technical team at our stage.
Montreal's French-English bilingual professional culture is also an operational advantage for a company that views European dairy protein markets as a priority alongside North American ones. The technical conversations about casein functionality that matter most to sophisticated dairy formulators in France, Switzerland, and the UK are conversations our team is equipped to have.
What animal-free means for the supply chain
Our production process requires no ongoing animal contact. The bovine mammary cell line was derived from tissue once; from that point forward, ongoing production uses cells that replicate and are maintained entirely in our facility. No milking, no calves, no grazing land. The closed-loop bioreactor uses water primarily as a culture media component, with recycling through our facility's water systems rather than the open consumption of irrigation water that conventional dairy requires.
We do not claim a certified life cycle assessment for our current pilot process, and we would not because the economics and energy inputs of pilot-scale production do not reflect what production-scale manufacturing will look like. What we can say is that the resource inputs at pilot scale per kilogram of protein are materially lower than published IDF benchmarks for conventional casein production, and the trajectory as we scale is toward further improvement rather than worse.
What comes next
Our immediate priorities are expanding the early-access formulation program, advancing our BC-1 specification to support a Health Canada novel food pre-submission, and developing our alpha-Lactalbumin and beta-Lactoglobulin fractions toward the same production-scale specification we have for BC-1.
We write about our work in this blog because the cell-ag and animal-free dairy protein field needs more transparent technical discussion from companies actually operating at production scale. The gap between what companies announce and what they can show in a formulation room has been wide enough in the past to generate justified skepticism from food manufacturers. We intend to contribute to closing that gap by reporting what we actually observe, including where our performance falls short of our goals and what we are doing about it.
If you are a food manufacturer evaluating animal-free dairy proteins, the best starting point is a formulation conversation. Our early-access program is the mechanism for that. The application is on our website.